Gender Differences in Serotonin Signaling in Patients with Diarrhea-predominant Irritable Bowel Syndrome

Ryo Katsumata¹, Akiko Shiotani¹, Takahisa Murao¹, Manabu Ishii¹, Minoru Fujita¹, Hiroshi Matsumoto¹ and Ken Haruma²

Abstract

Objective Gender differences, including differences in the prevalence, subtypes and the effectiveness of treatment, are generally recognized in irritable bowel syndrome (IBS). Although serotonin type 3 receptor (5-HT3R) antagonists appear to be more effective in women with diarrhea predominant IBS (IBS-D) than they are in men, the mechanisms underlying these effects remain unclear. The aim of the present was to investigate the gender differences in 5-HT signaling.

Methods The subjects were selected from outpatients with IBS-D and healthy controls. Their rectal mucosal S100A, tryptophan hydroxylase (TPH) and 5-HT transporter (5-HTT, SERT, SLC6A4) mRNA expression levels were measured. Clinical symptoms were evaluated using the gastrointestinal symptom rating scale (GSRS) and the self-rating depression scale (SDS).

Results The study population of 100 subjects included 47 IBS-D patients and 53 age- and gender-matched healthy controls. The S100A9 (5.20 vs. 1.90, p=0.001) and SLC6A4 (2.00 vs. 1.00, p=0.019) mRNA levels in the rectal mucosa of women with IBS-D were significantly higher than those in men. Among the healthy controls, the S100A10 expression levels in men were higher than those in women (1.33 vs. 0.82, p=0.005). The S100A8 and S100A10 expression levels in women with IBS-D were positively correlated with their diarrhea scores (r=0.55 and 0.58, p<0.05).

Conclusion 5-HT signaling might be a major contributor to the symptoms of IBS in men, and the differences may be associated with the effectiveness of 5-HT3R antagonists.

Key words: irritable bowel syndrome, serotonin, serotonin transporter, tryptophan hydroxylase, S100 A10

(Intern Med 56: 993-999, 2017) (DOI: 10.2169/internalmedicine.56.7674)
to require lower doses of 5-HT3R antagonists than men (6, 7).

5-HT is crucial neurotransmitter that affects both the central nervous system (CNS) and the gut; its signaling plays a pathophysiological role in IBS, especially in IBS-D (8). It has been suggested that the release of 5-HT contributes to the development of abdominal pain and regulates GI motility and secretion (9, 10). The synthesis of 5-HT is regulated by the rate-limiting enzyme tryptophan hydroxylase (TPH). Two isoforms of TPH exist: TPH1 is dominantly expressed in the peripheral organs, especially the gut, and TPH2 is primarily expressed in the CNS and the peripheral serotonergic neurons (11). 5-HT transporters (5-HTT, SERT, SLC6A4), which are located in the synaptic cleft, play an important role in regulating serotonergic signaling (12). 5-HTT was detected on the mucosal surface, especially on the epithelial cells of the crypt and the myenteric neurons using immunostaining (12, 13). It was previously reported that the TPH1 and SLC6A4 mRNA levels are decreased in the rectal mucosa of IBS patients and that they are associated with diarrhea and constipation symptoms (14).

S100 proteins consist of calcium-binding proteins and are involved in the regulation of the cytoplasmatic calcium concentration, signal transduction and various intracellular and extracellular functions (15, 16). Inflammatory and epithelial cells express S100A8 (also known as calgranulin A; myeloid-related protein 8, MRP8) and S100A9 (calgranulin B; MRP14). S100A8 and S100A9 are abundantly expressed throughout the lamina propria and the epithelial cells in the inflamed mucosa of patients with inflammatory bowel disease (IBD), but not in the non-inflamed mucosa (17, 18). Thus, these proteins and calprotectin (the hetero-complex formed by the non-covalent association of S100A8 and S100A9) are thought to be associated with gut inflammation and the pathogenesis of IBD (19-22). The fecal calprotectin levels are significantly increased in patients with IBD and are correlated with the clinical disease activity (23); this can be used to reliably differentiate between patients with IBD and IBS (24, 25). However, few papers have investigated the association between the mucosal expression of S100A8 or S100A9 and IBS (26). S100A10 (also known as p11) transports members of the voltage-gated sodium and potassium channel families and enhances the functional expression of acid-sensing ion channels (ASICs) (27), which play a key role in the activation and sensitization of the visceral nociceptors (28). S100A10 interacts and co-localizes with 5-HT 1B receptors (29), and its alteration is associated with depression (30). Previous studies evaluating the expression levels of S100A10 and SLC6A4 in the rectal and sigmoid mucosa of IBS patients and healthy controls confirmed the significant overexpression of S100A10 in the rectal mucosa of IBS-D patients (26, 31). However, no studies have so far investigated gender differences in the mucosal expression, and the specific role of 5-HT signaling in the pathophysiology and the gender differences of IBS remain unclear. Thus, to identify whether the expression levels of TPH1, S100A8, S100A9, S100A10 and SLC6A4 differ between the genders, we measured the mRNA levels in biopsy specimens taken from the rectal mucosa of IBS-D patients and healthy controls.

### Materials and Methods

We performed a case control study of IBS-D patients and age- and sex matched healthy controls. This study was approved by Kawasaki Medical School Ethical Committee. Written informed consent was obtained from each of the subjects.

### Subjects

Patients with IBS-D were diagnosed with IBS according to the Rome III criteria (32); IBS-D was subtyped if >25% of their stools were loose (mushy) or watery. Subjects with other subtypes of IBS, previous surgery of the GI tract and self-reported organic GI disorders (malignancy, inflammatory bowel disease, peptic ulcer, gall bladder disorder, pancreatitis or liver disease) were excluded.

The enrolled healthy controls were individuals who underwent a routine checkup and patients undergoing colon cancer screening who were positive for fecal occult blood, but otherwise demonstrated no meaningful findings.

### Biopsy sample

Experienced GI endoscopists performed colonoscopies. Rectal specimens were taken using endoscopic forceps (FB240U Olympus, Tokyo, Japan), and they were frozen with liquid nitrogen and stored until use at -80°C.

### RNA extraction and polymerase chain reaction

RNA extraction and a quantitative mRNA analysis of S100A8, S100A9, S100A10, TPH1 and SLC6A4 were performed using a reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR), as previously reported (33).

### Questionnaire

The GI symptom rating scale (GSRS) was performed to evaluate the clinical GI symptoms. The test consists of 15 questions on a scale of 1 to 7, and can evaluate the following five major GI symptoms: abdominal pain, reflux, diarrhea, indigestion and constipation (34). The subjective depressive status was assessed using a self-rating depression scale (SDS) that was composed of 20 questions; depression was defined as a total score of >50 (35).

### Analysis

Continuous and normally distributed values were expressed as the mean and standard deviation (SD). Categorical data or non-normally distributed continuous values were expressed as counts with the percentage or median and the interquartile range. Normal distribution and homoscedasticity were assessed using the Shapiro-Wilk test and the Levene test. Comparisons between two groups were tested

Intern Med 56: 993-999, 2017 DOI: 10.2169/internalmedicine.56.7674
Table 1. Comparison of Demographic Data, Questionnaire Scores, and mRNA Expressions between the IBS-D Patients and the Healthy Controls.

|                      | Controls (n=53) | IBS-D (n=47) | p     |
|----------------------|----------------|--------------|-------|
| Age mean (SD)        | 44.1 (16.0)    | 46.1 (18.3)  | 0.801a|
| Gender men (%)       | 32 (60)        | 29 (62)      | 0.892b|
| SDS scores median (IQR) | 34 (31-41)   | 42.5 (35-51)| <0.001c|
| GRS scores median (IQR) |              |              |       |
| Reflux               | 1 (1-1.5)      | 1.8 (1-3)    | 0.016c|
| Abdominal pain       | 1 (1-1.7)      | 2 (1.3-3)    | <0.001c|
| Indigestion          | 1.3 (1-1.5)    | 2.1 (1.3-2.8)| <0.001c|
| Diarrhea             | 1 (1.2-2)      | 5.2 (3.7-6)  | <0.001c|
| Constipation         | 1.3 (1-2)      | 2.3 (1.8-3)  | <0.001c|
| mRNA expression median (IQR) |        |              |       |
| TPH1 ×10⁻³           | 5.02 (4.12-8.11)| 6.19 (3.72-10.11)| 0.532c|
| S100A8 ×10⁻⁵         | 5.50 (2.00-11.50)| 3.00 (1.00-9.00)| 0.216c|
| S100A9 ×10⁻⁴         | 2.05 (1.30-6.40)| 2.80 (1.30-5.80)| 0.599c|
| S100A10 ×10⁻¹        | 1.06 (0.82-1.41)| 1.23 (0.99-1.48)| 0.148c|

IBS-D: diarrhea predominant irritable bowel syndrome, SDS: Self-rating Depression Scale, GRS: gastrointestinal symptom rating scale
p values calculated using: a: unpaired t-test, b: chi-squared test, c: Mann-Whitney U test

Table 2. Gender Differences of Age and Questionnaire Scores in IBS-D Patients.

|               | Men (n=29) | Women (n=18) | p     |
|---------------|------------|--------------|-------|
| Age mean (SD) | 46.4 (15.7)| 45.6 (22.4)  | 0.548a|
| SDS scores    | 44 (37-50) | 42 (36-46)   | 0.481c|
| GRS scores    |            |              |       |
| Reflux        | 2 (1-3)    | 1.5 (1-2)    | 0.617c|
| Abdominal pain| 1.8 (1.3-2.8)| 2.3 (1.5-4)| 0.301c|
| Indigestion   | 1.5 (1.3-2.1)| 2.3 (1.3-3)| 0.715c|
| Diarrhea      | 5 (3.5-8)  | 5.3 (4.5-8)  | 0.622c|
| Constipation  | 2.3 (1-3.3)| 2 (1.8-2.5)  | 0.571c|

IBS-D: diarrhea predominant irritable bowel syndrome, SDS: Self-rating Depression Scale, GRS: gastrointestinal symptom rating scale
p values calculated using: a: unpaired t-test, c: Mann-Whitney U test

Results

The study population included 47 IBS-D patients (29 men and 18 women) and 53 controls (32 men and 21 women). The GRS and SDS scores of the IBS-D patients were significantly higher than those of the controls (Table 1). These scores did not differ to a significant extent between the genders in patients with IBS-D (Table 2).

Discussion

The mRNA expression

The TPH1, S100A8, S100A9, S100A10 and SLC6A4 mRNA expression levels in the IBS-D patients and controls did not differ to a statistically significant extent (Table 1). The expression levels of S100A9 (5.20 vs. 1.90, p=0.001) and SLC6A4 (2.00 vs. 1.00, p=0.019) in women with IBS-D were those in men with IBS-D (Fig. 1). The expression levels of S100A10 in male controls were significantly higher than those in female controls (1.33 vs. 0.82, p=0.005) (Fig. 2) (Table 3).

The association between the mRNA expression levels and the clinical scores (Table 4)

There were some significant correlations between the mRNA expression and the GRS scores in the IBS-D patients. The S100A8, S100A9, and S100A10 expression levels were positively correlated with the diarrhea scores in the females (r=0.55, 0.44, and 0.58) (Fig. 3).

This is the first study to identify a gender difference in the expression levels of S100A4 and SLC6A4 in the rectal mucosa of IBS-D patients and healthy controls. The median S100A9 expression level in the female patients was significantly higher than that in the male patients. The association between gut micro-inflammation and the pathogenesis of IBS was previously reported (36). Shulman et al. reported that the gut permeability and an inflammatory status were associated with the severity of GI symptoms in IBS patients (37). Indeed, we demonstrated that S100A8 was positively correlated with the diarrhea and indigestion scores of the IBS-D patients. This result suggested that micro-
is known as post-infectious IBS (PI-IBS) (38). Thabane et al. identified that women were at greater risk of PI-IBS (39). However, the expression levels of S100A8 and S100A9 did not differ between our IBS-D patients and healthy controls, as previously reported (26, 31). Although gut inflammation was thought to be associated with the pathogenesis of IBS, its contribution might be small. In a previous meta-analysis, blood biochemical markers such as C-reactive protein (CRP) were not elevated in IBS patients and none of the biomarkers reliably distinguished between IBS and healthy controls (40). The inflammatory changes are so subtle that it might only be possible to confirm on a microscopic scale (41). Considering our results and our previous research, we assume in Japanese subjects, gut inflammation might make a greater contribution to the pathogenesis of IBS in women than it does in men.

In addition to S100A9, we confirmed SLC6A4 was significantly overexpressed in the rectal mucosa of female patients in comparison to male patients. A decrease in the expression of SLC6A4 in the intestinal mucosa, resulting in lower SLC6A4 activity was reported to be associated with the symptoms of diarrhea and constipation (13). Chen et al. (42) reported a high frequency of diarrhea in transgenic mice lacking the SLC6A4 gene. In practice, the use of selective 5-HT reuptake inhibitors (SSRI) induces diarrhea as an adverse event (43). An SSRI, paroxetine, was also reported to

---

**Table 3. Gender Differences of mRNA Expressions in the IBS-D Patients and the Controls.**

|          | IBS-D patients | Controls |
|----------|----------------|----------|
|          | Men (n=29)     | Women (n=18) | p   | Men (n=32) | Women (n=21) | p    |
| TPH1     | ×10^2          | 5.89 (2.76-8.70) | 6.00 (4.78-8.41) | 0.062 | 6.68 (4.45-9.28) | 4.79 (4.01-7.44) | 0.596 |
| S100A8   | ×10^5          | 2.00 (0.50-7.50) | 5.00 (2.00-2.30) | 0.198 | 5.00 (1.00-13.00) | 7.50 (2.50-11.50) | 0.487 |
| S100A9   | ×10^4          | 1.90 (1.05-3.00) | 5.20 (2.80-12.20) | 0.001 | 1.50 (1.20-7.00) | 2.35 (1.40-3.60) | 0.818 |
| S100A10  | ×10^1          | 1.22 (0.99-1.44) | 1.26 (0.94-1.47) | 0.948 | 1.33 (1.07-1.79) | 0.82 (0.76-1.03) | 0.005 |
| SLC6A4   | ×10^5          | 1.00 (0.1-1.50) | 2.00 (2.00-3.00) | 0.019 | - | - | - |

*IBS-D: diarrhea predominant irritable bowel syndrome, p values calculated using Mann-Whitney U test.*

---

**Figure 1.** The gender difference in the expression of S100A9 and SLC6A4 mRNA in the rectal mucosa of the IBS-D patients. Horizontal bar: median, Box: interquartile range, Vertical lines: the range of values. The p values were calculated using the non-parametric Mann-Whitney U test.

**Figure 2.** The gender difference in the expression of S100A10 in the rectal mucosa of the healthy controls. Horizontal bar: median, Box: interquartile range, Vertical lines: the range of values. The p values were calculated using the non-parametric Mann-Whitney U test.
increase the jejuna propagation velocity of phase III probably through the enhancement of 5-HT signaling (44). Thus, 5-HTT is thought to be associated with colonic motility and its reduction might lead to the facilitation of 5-HT signaling and impaired motility. The present results regarding the gender difference in the expression of 5-HTT is thought to be associated with colonic motility and impaired motility. The present results regarding the gender difference in the expression of 5-HTT is thought to be associated with colonic motility and impaired motility. The present results regarding the gender difference in the expression of 5-HTT is thought to be associated with colonic motility and impaired motility. The present results regarding the gender difference in the expression of 5-HTT is thought to be associated with colonic motility and impaired motility. The present results regarding the gender difference in the expression of 5-HTT is thought to be associated with colonic motility and impaired motility. The present results regarding the gender difference in the expression of 5-HTT is thought to be associated with colonic motility and impaired motility. The present results regarding the gender difference in the expression of 5-HTT is thought to be associated with colonic motility and impaired motility. The present results regarding the gender difference in the expression of 5-HTT is thought to be associated with colonic motility and impaired motility. The present results regarding the gender difference in the expression of 5-HTT is thought to be associated with colonic motility and impaired motility. The present results regarding the gender difference in the expression of 5-HTT is thought to be associated with colonic motility and impaired motility. The present results regarding the gender difference in the expression of 5-HTT is thought to be associated with colonic motility and impaired motility. The present results regarding the gender difference in the expression of 5-HTT is thought to be associated with colonic motility and impaired motility. The present results regarding the gender difference in the expression of 5-HTT is thought to be associated with colonic motility and impaired motility. The present results regarding the gender difference in the expression of 5-HTT is thought to be associated with colonic motility and impaired motility.

Women complain of diarrhea symptoms less frequently than men (45, 46). On a molecular scale, the 5-HT concentration in platelets of women was confirmed to be lower than that in men (47). Interestingly, the median S100A10 expression level in the rectum of healthy men was significantly higher than that in healthy women. Moreover, the expression of S100A10 was correlated with diarrhea symptoms in our female patients. This result might indicate that men are generally more susceptible to 5-HT than women; however, there was no gender difference in the rectal expression levels of S100A10 in IBS-D patients. This trend suggests that S100A10 may be an important factor, not only in the onset of IBS, but also in the severity of IBS-D. S100A10 is known to recruit the surface expression of 5HT type 4 receptor (5-HT₄R), leading its increase of concentration at the synapse thereby facilitating 5-HT₄R signaling (48, 49). In clinical practice, 5-HT₄R agonists are used to promote propulsive motility in the treatment of constipation (50).

Hence, S100A10 seems to be associated with the pathogenesis of IBS-D through hypersensitivity and the enhancement of GI motility; the overexpression of S100A10 has been confirmed in the rectal mucosa of IBS-D patients (26, 31).

Thus, the basic 5-HT signaling in men with IBS might receive greater stimulation due to the overexpression of S100A10 and the low expression of SLC6A4. This hypothesis is compatible with the fact that women appear to require lower doses of 5-HT₃R antagonists than men (4, 6). In our recent pilot study of biomarkers for predicting the effectiveness of ramosetron, the increased expression of S100A10 and TPH1 mRNA as well as TPH1 promoter and intronic SNPs appeared to predict higher 5-HT signaling, which is correlated with both diarrhea symptoms and the effectiveness of ramosetron in IBS-D patients (51). Moreover, the fact that 5-HT₄ agonists are more effective in women in comparison to men supports our hypothesis (52).

The present study was associated with some limitations. Firstly, the small number of cases might have induced a selection bias. A large-scale multicenter study is needed to minimize the influence of variation in the characteristics of the patients. Previous studies have reported a significant dif-

Table 4. Correlation between mRNA Expressions and Questionnaire Scores in the IBS-D Patients.

|                  | TPH1  | S100 A8 | S100 A9 | S100 A10 | SLC6A4 | TPH1  | S100 A8 | S100 A9 | S100 A10 | SLC6A4 |
|------------------|-------|---------|---------|----------|--------|-------|---------|---------|----------|--------|
| SDS              |       | -0.13   | -0.75   | 0.06     | 0.18   | 0.07  | -0.51   | -0.28   | -0.12    | 0.31   |
| GRS scores      |       |         |         |          |        |       |         |         |          |        |
| Reflux           | -0.89 | 0.03    | 0.23    | 0.25     | 0.13   | -0.09 | -0.09   | 0.19    | 0.25     |
| Abdominal pain   | 0.22  | 0.35    | 0.02    | 0.26     | 0.33   | 0.26  | -0.07   | -0.22   | 0.02     | 0.51   |
| Indigestion      | -0.17 | 0.42*   | 0.26    | 0.33     | 0.26   | -0.07 | -0.22   | 0.02    | 0.51     |
| Diarrhea         | -0.17 | 0.01    | 0.02    | 0.18     | 0.23   | 0.55*| 0.44    | 0.58*   | 0.42     |
| Constipation     | -0.13 | 0.3     | 0.16    | 0.12     | -0.85  | 0.41  | 0.46    | 0.05    | 0.19     | 0.14   |

*p<0.05, p values by Spearman’s correlation coefficient.

Figure 3. The correlation between the expression of S100A10 or S100A8 mRNA and the diarrhea scores of the gastrointestinal symptoms rating scale (GSRS). The p values were calculated using Spearman’s correlation coefficient.
ference in the number of immune cells in the sigmoid colon and ileum of IBS patients in comparison to healthy controls (53, 54). However, other studies evaluating the expression of S100A and SLC6A4 in the rectal and sigmoid mucosa of IBS patients and healthy controls indicated that the significant overexpression of S100A10 was only confirmed in the rectal mucosa of IBS-D patients (26, 31). Based on our previous study (26), we selected the rectum as a biopsy site in the present study. The evaluation of the right-side colon or performing biopsies at multiple sites may lead to different results. Another limitation is that our investigation was not based on microarray profiling and thus other genes may be significantly related to micro-inflammation and 5-HT signaling. Although we discussed the possible association between micro-inflammation and the pathogenesis of IBS, we did not confirm whether our subjects had a history of infectious colitis. This important factor should be identified in our next study. In addition, various other factors that influence the symptoms of IBS, such as ovarian hormones (55), interpersonal relationships (56), the autonomic nervous system and brain processing (include stress vulnerability) (57), might induce gender differences. However, the associations between these factors and the pathogenesis of IBS remain unclear. In particular, the effect of the menstrual cycle on the symptoms of is inadequately investigated in systemic reviews, and retrospective studies may overestimate the effect of the menstrual cycle on the symptoms of IBS and are less accurate than prospective assessments (2). Well-designed large-scale studies will be necessary to reveal the factors contributing to the clinical symptoms in IBS-D patients.

In conclusion, we identified gender differences in the expression of S100A and SLC6A4 in the rectal mucosa of IBS patients and healthy controls. Enhanced 5-HT signaling seems to make a greater contribution to the IBS symptoms of men, and the differences may be associated with the effectiveness of 5-HT3R antagonists. These gender differences may lead to a further understanding of the pathogenesis of IBS.

The authors state that they have no Conflict of Interest (COI).

References

1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 10: 712-721, 2012.
2. Adeyemo MA, Spiegel BM, Chang L. Meta-analysis: do irritable bowel syndrome symptoms vary between men and women? Aliment Pharmacol Ther 32: 738-755, 2010.
3. Shiotani A, Miyashita T, Takahashi T. Sex differences in irritable bowel syndrome in Japanese university students. J Gastroenterol 4: 562-568, 2006.
4. Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 13: 1149-1159, 1999.
5. Voß U, Lewerenz A, Nieber K. Treatment of irritable bowel syndrome: sex and gender specific aspects. Handb Exp Pharmacol 214: 473-497, 2012.
6. Fukudo S, Kinoshita Y, Okumura T, et al. Effect of ramucirumab on female patients with irritable bowel syndrome with diarrhea: a phase III long-term study. J Gastroenterol 150: 358-366.e8, 2016.
7. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel type 3 receptor antagonist ramucirumab in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 43: 1202-1211, 2008.
8. Miwa H. Prevalence of irritable bowel syndrome in Japan: Internet survey using Rome III criteria. Patient Prefer Adherence 2: 143-147, 2008.
9. Cremon C, Carini G, Wang B, et al. Intestinal release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 106: 1290-1298, 2011.
10. Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 95: 2699-2709, 2000.
11. Walther DJ, Peter JU, Bashammakh S, et al. Synthesis of by a second tryptophan hydroxylase isoform. Science 299: 76, 2003.
12. Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD, Gershon MD. Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J Neurosci 16: 2352-2364, 1996.
13. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal content and decreased reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 126: 1657-1664, 2004.
14. Kerckhoffs AP, ter Linde JJ, Akkermans LM, Samsom M. SERT and TPH1 mRNA expression are reduced in irritable bowel syndrome patients regardless of visceral sensitivity state in large intestine. Am J Physiol Gastrointest Liver Physiol 302: G1053-G1060, 2012.
15. Daub B, Schroeter M, Pfitter G, Ganitkevich V. Expression of members of the S100 Ca2+-binding protein family in guinea-pig smooth muscle. Cell Calcium 33: 1-10, 2003.
16. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 60: 540-551, 2003.
17. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 50: 3762-3771, 2004.
18. Roth J, Vogl T, Sorg C, Sunderkotter C. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol 24: 155-158, 2003.
19. Leach ST, Yang Z, Messina I, et al. Serum and mucosal S100 proteins, calprotectin ((S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol 42: 1321-1331, 2007.
20. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 58: 859-868, 2007.
21. Manolakis AC, Kapsoritakis AN, Tiaka EK, Potamianos SP. Calprotectin, calgranulin C, and other members of the S100 protein family in inflammatory bowel disease. Dig Dis Sci 56: 1601-1611, 2011.
22. Rana SV, Sharma S, Sinha SK, Parsad KK, Malik A, Singh K. Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients. Trop Gastroenterol 33: 251-256, 2012.
23. Tibble J, Teahan K, Thijssenfsson B, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 47: 506-513, 2000.
24. Carroccio A, Iacono G, Cottone M, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 49: 861-867, 2003.
25. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I.
Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119: 15-22, 2000.

26. Shiotani A, Kusunoki H, Kimura Y, et al. S100A expression and interleukin-10 polymorphisms are associated with ulcerative colitis and diarrhea predominant irritable bowel syndrome. Dig Dis Sci 58: 2314-2323, 2013.

27. Donier E, Rugiero F, Okuse K, Wood JN. Annexin II light chain p11 promotes functional expression of acid-sensing ion channel ASIC1a. J Biol Chem 280: 38666-38672, 2005.

28. Cervero F, Laird JM. Understanding the signaling and transmission of visceral nociceptive events. J Neurobiol 61: 49-54, 2004.

29. Svenningsson P, Chergui K, Rachleff I, et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 311: 77-80, 2006.

30. Alexander B, Warner-Schmidt J, Eriksson T, et al. Reversal of decreased behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med 2: 54ra76, 2010.

31. Camilleri M, Andrews CN, Bharucha AE, et al. Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology 132: 17-25, 2007.

32. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 130: 1480-1491, 2006.

33. Essien BE, Grasberger H, Romain RD, et al. ZBP-89 regulates expression of tryptophan hydroxylase I and mucosal defense against Salmonella typhimurium in mice. Gastroenterology 144: 1466-1477, 2013.

34. Svedlund J, Sjodin I, Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 33: 129-134, 1988.

35. Zang W. A self-rating depression scale. Arch Gen Psychiatry 12: 63-70, 1965.

36. Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 122: 1778-1783, 2002.

37. Shulman RJ, Jarrett ME, Cain KC, Broussard EK, Heitkemper MM. Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome. J Gastroenterol 49: 1467-1476, 2014.

38. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 136: 1979-1988, 2009.

39. Thabane M, Simunovic M, Akhtar-Danesh N, Marshall JK. Development and validation of a risk score for post-infectious irritable bowel syndrome. Am J Gastroenterol 104: 2267-2274, 2009.

40. Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 110: 444-454, 2015.

41. Kirsch R, Riddell RH. Histopathological alterations in irritable bowel syndrome. Mod Pathol 19: 1638-1645, 2006.

42. Chen JJ, Li Z, Pan H, et al. Maintenance of interstitial mucosa and ganglia of mice that lack the high-affinity transporter: Abnormal intestinal motility and the expression of cation transporters. J Neurosci 21: 6348-6361, 2001.

43. Spigset O. Adverse reactions of selective reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 20: 277-287, 1999.

44. Gorard DA, Libby GW, Farthing MJ. 5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake. Gut 35: 496-500, 1994.

45. Heitkemper MM, Chang L. Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome? Gend Med 6: 152-167, 2009.

46. Herman J, Pokkunuri V, Braham L, Pimentel M. Gender distribution in irritable bowel syndrome is proportional to the severity of constipation relative to diarrhea. Gend Med 7: 240-246, 2010.

47. Franke L, Schmidtmann R, Riedl A, van der Voort I, Uebelhack R, Mönikes H. Serotonin transporter activity and concentration in platelets of patients with irritable bowel syndrome: effect of gender. J Gastroenterol 45: 389-398, 2010.

48. Warner-Schmidt JL, Fialojet M, Maller A, et al. Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation. J Neurosci 29: 1937-1946, 2009.

49. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71: 533-554, 2002.

50. Hoffman JM, Tyler K, MacEachern SJ, et al. Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology 142: 844-854, 2012.

51. Shiotani A, Kusunoki H, Ishii M, Imanura H, et al. Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1. Neurogastroenterol Motil 27: 82-91, 2015.

52. Heitkemper M, Jarrett M, Bond EF, Chang L. Impact of sex and gender on irritable bowel syndrome. Biol Res Nurs 5: 56-65, 2003.

53. Di Nardo G, Barbara G, Cucchiara S, et al. Neuroimmune interactions at different intestinal sites are related to abdominal pain symptoms in children with IBS. Neurogastroenterol Motil 26: 196-204, 2014.

54. Gonzalez-Castro AM, Martinez C, Salvo-Romero E, et al. Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in Irritable Bowel Syndrome. J Gastroenterol Hepatol 2016 (Epub ahead of print).

55. Meleine M, Matricon J. Gender-related differences in irritable bowel syndrome: potential mechanisms of sex hormones. World J Gastroenterol 20: 6725-6743, 2014.

56. Thakur ER, Gurtman MB, Keefer L, Brenner DM, Lackner JM. Gender differences in irritable bowel syndrome: the interpersonal connection. Neurogastroenterol Motil 27: 1478-1486, 2015.

57. Bale TL, Epperson CN. Sex differences and stress across the lifespan. Nat Neurosci 18: 1413-1420, 2015.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).